Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 5Recruiting 4Completed 4Terminated 3Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Non-Hodgkin 11Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Pancreatic Neoplasms 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 24Cyclophosphamide 14fludarabine 8Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5fludarabine phosphate 4Carboplatin 4venetoclax 3obinutuzumab 3ibrutinib 3atezolizumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Cytarabine 3Carmustine 3Bortezomib 3Bendamustine Hydrochloride 3ublituximab 2pembrolizumab 2pegfilgrastim 2ibritumomab tiuxetan 2Tiragolumab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Indium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell × Bendamustine Hydrochloride × Clear all
NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Thomas Jefferson University

Phase 1 Terminated
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Fate Therapeutics

Phase 1 Terminated
98 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡